Central Bank & Trust Co. Purchases 61 Shares of Thermo Fisher Scientific Inc. (NYSE:TMO)

Central Bank & Trust Co. grew its holdings in Thermo Fisher Scientific Inc. (NYSE:TMO) by 3.2% in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 1,994 shares of the medical research company’s stock after acquiring an additional 61 shares during the quarter. Central Bank & Trust Co.’s holdings in Thermo Fisher Scientific were worth $992,000 at the end of the most recent reporting period.

A number of other large investors have also bought and sold shares of the business. Wedge Capital Management L L P NC increased its stake in Thermo Fisher Scientific by 957.5% in the 1st quarter. Wedge Capital Management L L P NC now owns 7,466 shares of the medical research company’s stock valued at $3,715,000 after buying an additional 6,760 shares during the last quarter. Kennebec Savings Bank increased its stake in shares of Thermo Fisher Scientific by 9.9% during the 1st quarter. Kennebec Savings Bank now owns 1,357 shares of the medical research company’s stock worth $675,000 after purchasing an additional 122 shares during the last quarter. KMG Fiduciary Partners LLC increased its position in Thermo Fisher Scientific by 11.1% during the first quarter. KMG Fiduciary Partners LLC now owns 5,038 shares of the medical research company’s stock worth $2,507,000 after buying an additional 503 shares during the last quarter. ARS Wealth Advisors Group LLC raised its stake in Thermo Fisher Scientific by 1.6% in the 1st quarter. ARS Wealth Advisors Group LLC now owns 1,563 shares of the medical research company’s stock valued at $778,000 after acquiring an additional 25 shares during the period. Finally, Miracle Mile Advisors LLC lifted its stake in shares of Thermo Fisher Scientific by 1.7% during the 1st quarter. Miracle Mile Advisors LLC now owns 5,603 shares of the medical research company’s stock worth $2,788,000 after buying an additional 93 shares during the last quarter. 89.23% of the stock is owned by institutional investors.

Thermo Fisher Scientific Stock Performance

Shares of Thermo Fisher Scientific stock opened at $401.99 on Friday. The company has a 50 day moving average price of $420.74 and a 200 day moving average price of $495.81. The firm has a market capitalization of $151.75 billion, a P/E ratio of 24.32, a PEG ratio of 2.99 and a beta of 0.78. Thermo Fisher Scientific Inc. has a 52 week low of $390.50 and a 52 week high of $627.88. The company has a quick ratio of 1.29, a current ratio of 1.66 and a debt-to-equity ratio of 0.59.

Thermo Fisher Scientific (NYSE:TMO) last released its quarterly earnings data on Wednesday, April 23rd. The medical research company reported $5.15 earnings per share for the quarter, beating analysts’ consensus estimates of $5.10 by $0.05. Thermo Fisher Scientific had a return on equity of 17.51% and a net margin of 14.78%. The business had revenue of $10.36 billion during the quarter, compared to analyst estimates of $10.23 billion. During the same quarter last year, the business posted $5.11 EPS. The company’s revenue was up .2% on a year-over-year basis. Sell-side analysts expect that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current year.

Thermo Fisher Scientific Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Tuesday, July 15th. Shareholders of record on Friday, June 13th will be issued a $0.43 dividend. The ex-dividend date of this dividend is Friday, June 13th. This represents a $1.72 annualized dividend and a yield of 0.43%. Thermo Fisher Scientific’s payout ratio is 10.09%.

Insider Transactions at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, SVP Michael A. Boxer sold 3,775 shares of the business’s stock in a transaction on Monday, March 10th. The shares were sold at an average price of $532.52, for a total value of $2,010,263.00. Following the completion of the transaction, the senior vice president now owns 10,816 shares in the company, valued at $5,759,736.32. The trade was a 25.87% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, EVP Gianluca Pettiti sold 300 shares of the business’s stock in a transaction on Monday, April 28th. The stock was sold at an average price of $429.93, for a total value of $128,979.00. Following the transaction, the executive vice president now directly owns 23,167 shares of the company’s stock, valued at $9,960,188.31. The trade was a 1.28% decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 0.33% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts have recently weighed in on TMO shares. Barclays dropped their target price on Thermo Fisher Scientific from $620.00 to $475.00 and set an “equal weight” rating for the company in a report on Thursday, April 10th. Robert W. Baird dropped their target price on shares of Thermo Fisher Scientific from $603.00 to $573.00 and set an “outperform” rating for the company in a research report on Thursday, April 24th. Citigroup decreased their target price on Thermo Fisher Scientific from $650.00 to $570.00 and set a “neutral” rating on the stock in a research report on Tuesday, March 4th. Royal Bank of Canada decreased their price target on shares of Thermo Fisher Scientific from $651.00 to $637.00 and set an “outperform” rating on the stock in a report on Thursday, April 24th. Finally, Evercore ISI dropped their price objective on shares of Thermo Fisher Scientific from $585.00 to $500.00 and set an “outperform” rating for the company in a research note on Thursday, April 24th. Four investment analysts have rated the stock with a hold rating and seventeen have given a buy rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $605.30.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.